Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
U.S. stocks finished Monday sharply lower, with the Nasdaq Composite falling 2.49%, the S&P 500 losing 1.92% and the Dow Jones Industrial Average declining 739.38 points. The markets realized losses across large-cap and small-cap shares, while the Cboe Volatility Index jumped 22.06%…
A Precision-Oncology Bet With Room to Grow
Eli Lilly and Company (NYSE: LLY) is adding another potential growth engine to a business already well acquainted with acceleration. On November 16, Calytrix Bio announced a definitive agreement to be acquired by Lilly in…
A Rocket Comes Home, and the Business Case Gets Bigger
SpaceX (NASDAQ: SPCX) has given many a compelling reason to look beyond the launchpad and toward the income statement. On November 14, the company caught its Starship upper stage with the launch…
A 68% Reduction in Recurrence Risk Sharpens the Growth Story
CG Oncology (NASDAQ: CGON) has delivered the kind of late-stage cancer result that can move a biotechnology company from promising science toward a more substantial commercial proposition. On November 16, the company…
A Legal AI Story With Evidence Attached
Artificial intelligence has produced no shortage of opening statements. CS Disco, Inc. (NYSE: LAW) is beginning to assemble something more persuasive: evidence. The Austin-based litigation technology company reported third-quarter 2026 revenue of $45.3 million, an 11%…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Flight 15 Puts the Economics of Reusable Rockets in Focus
SpaceX (NASDAQ: SPCX) is preparing for a test that could bring its most ambitious rocket closer to becoming its most consequential business asset. Starship Flight 15 is targeting a November 13 launch…
SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution
For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…
